London, UK – October 11, 2021 – ÌÇÐÄlogoÃ×·ÆÍà (Element) has acquired Nanosyn, a full-service pharmaceuticals contract development and manufacturing organization, significantly strengthening Element’s offering for pharmaceutical and biopharmaceutical customers in North America.
Nanosyn is a leader in drug discovery and small-batch manufacturing of active pharmaceutical ingredients. It has a track record of providing the highest quality services and operates three facilities in the San Francisco Bay Area of approximately 100,000 sq.ft, two of which are FDA registered.
With a team of more than 75 scientists and experts, more than half of whom have a PhD in a scientific discipline, Nanosyn will bolster Element’s breadth of technical services bringing cutting edge innovation and high growth. The team will support pharmaceuticals and biopharmaceuticals customers from early-stage discovery, through clinical trials, formulation, and regulatory approval.
Jo Wetz, ÌÇÐÄlogoÃ×·ÆÍÃCEO, said: “This is our fifth acquisition in the life sciences sector this year. Following this growth, it is now the ÌÇÐÄlogoÃ×·ÆÍÃGroup’s most significant end market, covering pharmaceuticals, medical devices and environmental testing services.
“Nanosyn complements Element’s life sciences offering by extending our services to include drug discovery and small-scale manufacturing for drug development, making us a source of support and true partner for the full value chain. Nanosyn has a deep customer base that includes several of the top pharmaceutical companies in the world, and it supports the development of Element’s position as a full-service solutions provider.”
Nikolai Sepetov PhD, Nanosyn CEO, said: “Joining Element’s global family is a great opportunity for us and will allow our business to leverage its resources and expertise around the world. Nanosyn has a 23 year track record of supporting numerous drug discovery and development programs which have led to over fifty clinical candidates and several marketed drugs. We are proud of our strong reputation for continuously providing outstanding services based on cutting edge science. Joining ÌÇÐÄlogoÃ×·ÆÍÃas it expands its life sciences offering will create the opportunity for us to be at the forefront of progress and development in the pharmaceutical industry.”
About ÌÇÐÄlogoÃ×·ÆÍÃ
The ÌÇÐÄlogoÃ×·ÆÍà Group is one of the world’s leading global providers of testing, inspection and certification services for a diverse range of products, materials and technologies in advanced industrial supply chains where failure in use is not an option. Headquartered in London, UK, Element’s scientists, engineers and technologists, working in our global network of over 200 laboratories, support customers from early R&D, through complex regulatory approvals and into production ensuring their products are safe, sustainable and achieve market access.
For more information about Element, please visit our website, connect with us on and and subscribe to our channel.
BroadOak Capital Partners served as Nanosyn’s exclusive financial adviser on the transaction.
Media contacts:
Devan LaBrash, Pagoda Public Relations
T: +44 (0) 131 556 0770
E: devan.labrash@pagodapr.com
“Nanosyn complements Element’s life sciences offering by extending our services to include drug discovery and small-scale manufacturing for drug development, making us a source of support and true partner for the full value chain. Nanosyn has a deep customer base that includes several of the top pharmaceutical companies in the world, and it supports the development of Element’s position as a full-service solutions provider.”
Jo Wetz
CEO